Mercer Global Advisors Inc. ADV Purchases New Position in ImmunityBio, Inc. (NASDAQ:IBRX)

Mercer Global Advisors Inc. ADV acquired a new position in ImmunityBio, Inc. (NASDAQ:IBRX) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 19,904 shares of the company’s stock, valued at approximately $126,000.

Several other large investors have also recently made changes to their positions in the stock. Bleakley Financial Group LLC acquired a new position in shares of ImmunityBio in the 1st quarter valued at about $58,000. Lazard Asset Management LLC boosted its position in shares of ImmunityBio by 102.6% during the first quarter. Lazard Asset Management LLC now owns 13,019 shares of the company’s stock worth $68,000 after buying an additional 6,593 shares during the period. Copperwynd Financial LLC acquired a new stake in ImmunityBio in the fourth quarter valued at $79,000. Axxcess Wealth Management LLC acquired a new position in ImmunityBio in the first quarter valued at approximately $85,000. Finally, Brookstone Capital Management acquired a new position in ImmunityBio in the first quarter valued at $100,000. 8.58% of the stock is owned by institutional investors.

ImmunityBio Stock Performance

IBRX stock opened at $3.60 on Wednesday. The firm has a market cap of $2.49 billion, a P/E ratio of -3.30 and a beta of 1.02. The stock has a 50-day simple moving average of $4.07 and a 200-day simple moving average of $5.59. ImmunityBio, Inc. has a 1 year low of $1.25 and a 1 year high of $10.53.

ImmunityBio (NASDAQ:IBRX) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The business had revenue of $1.05 million for the quarter, compared to the consensus estimate of $2.53 million. On average, equities research analysts predict that ImmunityBio, Inc. will post -0.86 EPS for the current year.

Analyst Ratings Changes

Separately, Piper Sandler decreased their price target on ImmunityBio from $6.00 to $4.75 and set a “neutral” rating on the stock in a research note on Monday, August 19th.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.